Channelpedia

PubMed 23424202


Referenced in: Kv10.1

Automatically associated channels: Kv10.1 , Kv6.3



Title: Behavioural and functional characterization of Kv10.1 (Eag1) knockout mice.

Authors: Roser Ufartes, Tomasz Schneider, Lena Sünke Mortensen, Camino de Juan Romero, Klaus Hentrich, Hendrik Knoetgen, Vadim Beilinson, Wiebke Moebius, Victor Tarabykin, Frauke Alves, Luis A Pardo, J Nicholas P Rawlins, Walter Stuehmer

Journal, date & volume: Hum. Mol. Genet., 2013 Jun 1 , 22, 2247-62

PubMed link: http://www.ncbi.nlm.nih.gov/pubmed/23424202


Abstract
Kv10.1 (Eag1), member of the Kv10 family of voltage-gated potassium channels, is preferentially expressed in adult brain. The aim of the present study was to unravel the functional role of Kv10.1 in the brain by generating knockout mice, where the voltage sensor and pore region of Kv10.1 were removed to render non-functional proteins through deletion of exon 7 of the KCNH1 gene using the '3 Lox P strategy'. Kv10.1-deficient mice show no obvious alterations during embryogenesis and develop normally to adulthood; cortex, hippocampus and cerebellum appear anatomically normal. Other tests, including general health screen, sensorimotor functioning and gating, anxiety, social behaviour, learning and memory did not show any functional aberrations in Kv10.1 null mice. Kv10.1 null mice display mild hyperactivity and longer-lasting haloperidol-induced catalepsy, but there was no difference between genotypes in amphetamine sensitization and withdrawal, reactivity to apomorphine and haloperidol in the prepulse inhibition tests or to antidepressants in the haloperidol-induced catalepsy. Furthermore, electrical properties of Kv10.1 in cerebellar Purkinje cells did not show any difference between genotypes. Bearing in mind that Kv10.1 is overexpressed in over 70% of all human tumours and that its inhibition leads to a reduced tumour cell proliferation, the fact that deletion of Kv10.1 does not show a marked phenotype is a prerequisite for utilizing Kv10.1 blocking and/or reduction techniques, such as siRNA, to treat cancer.